advertisement
 

  Back to News Research News and Information

Current Research News

    18 January 2017

  1. [New!] Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.
  2. [New!] First Infant Formula Type and Risk of Islet Autoimmunity in The Environmental Determinants of Diabetes in the Young (TEDDY) Study.
  3. [New!] Diet Quality during Infancy and Early Childhood in Children with and without Risk of Type 1 Diabetes: A DEDIPAC Study. Free full text available in HTML and PDF via link.
  4. [New!] Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept.

    11 January 2017

  5. Detection of enteroviruses in stools precedes islet autoimmunity by several months: possible evidence for slowly operating mechanisms in virus-induced autoimmunity.
  6. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
  7. Is islet transplantation a realistic approach to curing diabetes? Free full text available in HTML and PDF formats.
  8. "Learning" Can Improve the Blood Glucose Control Performance for Type 1 Diabetes Mellitus.
  9. Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. Free full text available in HTML and PDF formats.

    4 January 2017

  10. Bionic pancreas system successfully controls blood sugar without risk of hypoglycemia reports on Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover tria, previously reported.
  11. Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3. Free full text available in HTML and PDF formats.
  12. The influence of sex on hyperfiltration in patients with uncomplicated type 1 diabetes.
  13. Extending Halogen-based Medicinal Chemistry to Proteins. See also Chemically modified insulin is available more quickly.
  14. Harvard biologist retracts diabetes breakthrough in Cell. See also Retraction Notice to: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation.

    28 December 2016

  15. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. See also Bionic pancreas system manages blood sugar levels in patients with type 1 diabetes living at home.
  16. Aggregation of Engineered Human β-Cells Into Pseudoislets: Insulin Secretion and Gene Expression Profile in Normoxic and Hypoxic Milieu. Free full text available in HTML and PDF formats.
  17. Vitamin D on Early Stages of Diabetic Kidney Disease: A Cross-sectional Study in Patients with Type 1 Diabetes Mellitus.

    21 December 2016

  18. Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery.
  19. MD-Logic Overnight Type 1 Diabetes Control in Home Settings: Multicenter, Multinational, Single blind, Randomized Trial.
  20. Incidence of type 1 diabetes has doubled in Kuwaiti children 0-14 years over the last 20 years.
  21. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog® in subjects with type 1 diabetes.
  22. Evaluation of the Counter-regulatory Responses to Hypoglycemia in Patients with Type 1 Diabetes during Opiate Receptor Blockade with Naltrexone.

    14 December 2016

  23. β-cell–mimetic designer cells provide closed-loop glycemic control.
  24. Coxsackie-adenovirus receptor expression is enhanced in pancreas from patients with type 1 diabetes. Free full text available in HTML and PDF formats.
  25. Metformin in adults with type 1 diabetes: design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): an international multicentre trial.

    7 December 2016

  26. Assessing the population impact of low rates of vitamin D supplementation on type 1 diabetes using a new statistical method. Free full text available in HTML and PDF formats.
  27. Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity. Free full text available in PDF format. See also Breakthrough in diabetes research: Pancreatic cells produce insulin instead of glucagon upon artemisinin treatment and Anti-malaria drugs could be linked to type 1 diabetes treatment.
  28. Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells. Free full text available in HTML and PDF formats. See also CRISPR editing in pancreatic cells reduced cell death, increased insulin secretion.
  29. Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Free full text available in HTML and PDF formats.
  30. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry.

    30 November 2016

  31. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
  32. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
  33. A parasite-derived 68-mer peptide ameliorates autoimmune disease in murine models of Type 1 diabetes and multiple sclerosis.
  34. Oxygenation of the Intraportally Transplanted Pancreatic Islet. Free full text available in HTML and PDF formats.

    23 November 2016

  35. Imbalance of bacteriome profiles within the Finnish Diabetes Prediction and Prevention study: Parallel use of 16S profiling and virome sequencing in stool samples from children with islet autoimmunity and matched controls.
  36. Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus.
  37. A comprehensive microbiological safety approach for agarose encapsulated porcine islets intended for clinical trials.

    16 November 2016

  38. A Novel Insulin/Glucose Model after a Mixed-Meal Test in Patients with Type 1 Diabetes on Insulin Pump Therapy. Free full text available in HTML and PDF formats.
  39. Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial.
  40. Associations between long chain polyunsaturated fatty acids and cardiovascular lipid risk factors in youth with type 1 diabetes: SEARCH Nutrition Ancillary Study.
  41. Islet cell transplantation improves nerve conduction velocity in type 1 diabetes compared with intensive medical therapy over six years.
  42. Optimizing Porcine Islet Isolation to Markedly Reduce Enzyme Consumption Without Sacrificing Islet Yield or Function. Free full text available in HTML and PDF formats.

    9 November 2016

  43. Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial.
  44. Efficacy of an Overnight Predictive Low-Glucose Suspend System in Relation to Hypoglycemia Risk Factors in Youth and Adults With Type 1 Diabetes.
  45. A Review of Safety and Design Requirements of the Artificial Pancreas. Free full text available in HTML and PDF formats.
  46. Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes.
  47. Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes.
  48. Increased Proliferation of the Pancreatic Duct Gland Compartment in Type 1 Diabetes. Free full text available in PDF format.
  49. The Association of Arsenic Exposure and Metabolism With Type 1 and Type 2 Diabetes in Youth: The SEARCH Case-Control Study.
  50. Peptide serum markers in islet autoantibody-positive children. See also Proteins as an early warning system for type 1 diabetes?
  51. No Contribution of GAD-65 and IA-2 Autoantibodies around Time of Diagnosis to the Increasing Incidence of Juvenile Type 1 Diabetes: A 9-Year Nationwide Danish Study.
  52. Vitamin D-binding protein and 25-hydroxyvitamin D during pregnancy in mothers whose children later developed type 1 diabetes.
  53. Low vitamin D level in pediatric patients with new onset type 1 diabetes is common, especially if in ketoacidosis.
  54. Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0-29 years: The population-based CINECA-SID ARNO Observatory, 2002-2012.

    2 November 2016

  55. Risk of future microvascular and macrovascular disease in people with Type 1 diabetes of very long duration: a national study with 10-year follow-up.
  56. Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.
  57. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.
  58. Immunogenicity of human embryonic stem cell-derived beta cells.
  59. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. See also UMMS researchers isolate immune cells from the islets of donors with type 1 diabetes.
  60. Insulitis in human diabetes: a histological evaluation of donor pancreases.
  61. Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes. Free full text available in HTML and PDF formats.
  62. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice.

    25 October 2016

  63. Using uncertain data from body-worn sensors to gain insight into type 1 diabetes. Free full text available in HTML and PDF formats.
  64. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
  65. Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications.
  66. Phototherapy and Risk of Type 1 Diabetes.

    19 October 2016

  67. Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D.
  68. A description of clinician reported diagnosis of type 2 diabetes and other non-type 1 diabetes included in a large international multicentered pediatric diabetes registry (SWEET).
  69. Stimulated urine C-peptide creatinine ratio vs serum C-peptide level for monitoring of β-cell function in the first year after diagnosis of Type 1 diabetes.

    12 October 2016

  70. Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.
  71. Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action.
  72. Pharmacological properties of faster-acting insulin aspart versus insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomised, double-blind, crossover trial.
  73. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
  74. Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
  75. GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.
  76. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. See also New approach to treating type 1 diabetes aims to limit damage caused by our own immune system.
  77. A roadmap of the generation of neoantigens as targets of the immune system in type 1 diabetes. Free full text available in HTML and PDF formats.

    5 October 2016

  78. Evaluating the Experience of Children With Type 1 Diabetes and Their Parents Taking Part in an Artificial Pancreas Clinical Trial Over Multiple Days in a Diabetes Camp Setting.
  79. Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial.
  80. Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case–control study. Free full text available in HTML and PDF formats.
  81. Compensatory Hyper-Connectivity in Developing Brains of Young Children with Type 1 Diabetes.
  82. Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes.
  83. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study.
  84. Neurocognitive consequences of diabetes.

    28 September 2016

  85. Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study.
  86. Tissue-Specific Stem Cells Obtained by Reprogramming of Non-Obese Diabetic (NOD) Mouse-Derived Pancreatic Cells Confer Insulin Production in Response to Glucose. Free full text available in HTML and PDF formats.
  87. Timing of Allergenic Food Introduction to the Infant Diet and Risk of Allergic or Autoimmune Disease: A Systematic Review and Meta-analysis.
  88. Glycemic variability predicts inflammation in adolescents with type 1 diabetes.
  89. Is the incidence of type 1 diabetes in children and adolescents stabilising? The first 6 years of a National Register.
  90. Glycemic Control Indices and Their Aggregation in the Prediction of Nocturnal Hypoglycemia From Intermittent Blood Glucose Measurements.
  91. Anti-Thymocyte Globulin + G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders with Established Type 1 Diabetes.
  92. The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus.
  93. Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival. Free full text available in HTML and PDF formats.

    21 September 2016

  94. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. PDF available with free JAMA account login.
  95. Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes.
  96. Modelling Day-to-Day Variability of Glucose-Insulin Regulation over 12-Week Home Use of Closed-Loop Insulin Delivery. Free full text available in PDF format.
  97. Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes.
  98. Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data.
  99. Thinking outside the insulin box: McMaster researchers link improved muscle health to better outcomes for people with diabetes. See also Myostatin inhibition therapy for insulin-deficient type 1 diabetes and Decreased Satellite Cell Number and Function in Humans and Mice With Type 1 Diabetes Mellitus is the Result of Altered Notch Signaling.

    14 September 2016

  100. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial.
  101. A minimized human insulin-receptor-binding motif revealed in a Conus geographus venom insulin. See also Snails' speedy insulin: Bio-inspired insulin may act three times faster than current products and Snail venom holds key to better diabetes treatments.
  102. Increased skin autofluorescence of children and adolescents with type 1 diabetes despite a well-controlled HbA1c: results from a cohort study. Free full text available in HTML and PDF formats.
  103. Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes.
  104. Incomplete immune response to coxsackie B viruses associates with early autoimmunity against insulin.
  105. Coincidence of PTPN22 c.1858CC and FCRL3 -169CC genotypes as a biomarker of preserved residual β-cell function in children with type 1 diabetes.
  106. Beta cell function and ongoing autoimmunity in long-standing, childhood onset type 1 diabetes.
  107. Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years.
  108. Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes. Free full text available in HTML and PDF formats.

    7 September 2016

  109. Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study. Free full text available in HTML and PDF formats.

    31 August 2016

  110. Broad-Spectrum Antibiotic Treatment and Subsequent Childhood Type 1 Diabetes: A Nationwide Danish Cohort Study. Free full text available in HTML and PDF formats.
  111. Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes.
  112. Long-term improvement in glucose control and counterregulation by islet transplantation for type 1 diabetes.

    24 August 2016

  113. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. Free full text available in HTML and PDF formats.
  114. β-cell replacement sources for type 1 diabetes: a focus on pancreatic ductal cells. Free full text available in HTML and PDF formats.
  115. Enterovirus infection of human islets of Langerhans affects β-cell function resulting in disintegrated islets, decreased glucose stimulated insulin secretion and loss of Golgi structure. Free full text available in HTML and PDF formats.
  116. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. See also Antibiotic Therapy During Infancy Increases Type 1 Diabetes Risk in Mice.
  117. The prevalence of small intestinal bacterial overgrowth (SIBO) in adult patients with type 1 diabetes and relationship with metabolic control and the presence of chronic complications of the disease. Free full text available in PDF format.
  118. Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes.
  119. Mixed success for Victoza in type 1 diabetes trials.

    17 August 2016

  120. Effectiveness of a Predictive Algorithm in the Prevention of Exercise-Induced Hypoglycemia in Type 1 Diabetes.
  121. Effect of autoimmunity risk loci on the honeymoon phase in type 1 diabetes.

    10 August 2016

  122. Islet transplantation provides superior glycemic control with less hypoglycemia compared to continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injections (MDI).
  123. Well, I Wouldn't be Any Worse Off, Would I, Than I am Now? A Qualitative Study of Decision-Making, Hopes, and Realities of Adults With Type 1 Diabetes Undergoing Islet Cell Transplantation.
  124. Duration of Action of Two Insulin Glargine Products, LY2963016 Insulin Glargine and Lantus® Insulin Glargine, in Subjects with Type 1 Diabetes Mellitus.
  125. Lipid Changes During Basal Insulin Peglispro, Insulin Glargine, or NPH Treatment in 6 IMAGINE Trials.
  126. Is there a role for gut microbiota in type 1 diabetes pathogenesis?

    3 August 2016

  127. New Devices Will 'Revolutionize' T1 Diabetes Care.
  128. Hypoglycemia Detection and Carbohydrate Suggestion in an Artificial Pancreas.
  129. Combination high-dose omega-3 fatty acids and high-dose cholecalciferol in new onset type 1 diabetes: a potential role in preservation of beta-cell mass. Free full text available in PDF format.
  130. Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis.
  131. Cardiac Assessment of Patients With Type 1 Diabetes Median 10 Years After Successful Simultaneous Pancreas and Kidney Transplantation Compared With Living Donor Kidney Transplantation.

[ Current Research News | News from 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 ]



                 
  Home Return to Top

Last Updated: Wednesday January 18, 2017 20:46:49
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
By using this site, you agree to our Terms of Use, Legal Notice, and Privacy Policy.
© Children with Diabetes, Inc. 1995-2017. Comments and Feedback.